West Pharmaceutical Services, Inc. (NYSE: WST) closed the day trading at $399.39 up 3.54% from the previous closing price of $385.75. In other words, the price has increased by $+13.64 from its previous closing price. On the day, 802882 shares were traded.
Ratios:
For a better understanding of WST, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 70.54. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 07, 2024, Upgraded its rating to Buy and sets its target price to $536 from $323 previously.
On June 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $390 to $405.
Stephens Upgraded its Equal-Weight to Overweight on April 11, 2023, whereas the target price for the stock was revised from $330 to $400.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Winters Chad sold 815 shares for $358.82 per share. The transaction valued at 292,436 led to the insider holds 1,309 shares of the business.
Witherspoon Charles sold 2,019 shares of WST for $724,061 on Feb 28 ’24. The VP & Treasurer now owns 1,979 shares after completing the transaction at $358.62 per share. On Feb 27 ’24, another insider, Green Eric Mark, who serves as the President, CEO and Board Chair of the company, sold 64,132 shares for $359.85 each. As a result, the insider received 23,077,971 and left with 152,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WST now has a Market Capitalization of 29.24B and an Enterprise Value of 28.69B. As of this moment, West’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.71, and their Forward P/E ratio for the next fiscal year is 43.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.91 while its Price-to-Book (P/B) ratio in mrq is 10.19. Its current Enterprise Value per Revenue stands at 9.73 whereas that against EBITDA is 33.98.
Stock Price History:
Over the past 52 weeks, WST has reached a high of $415.73, while it has fallen to a 52-week low of $310.42. The 50-Day Moving Average of the stock is 365.73, while the 200-Day Moving Average is calculated to be 367.54.
Shares Statistics:
Over the past 3-months, WST traded about 547.75K shares per day on average, while over the past 10 days, WST traded about 591.32k shares per day. A total of 73.50M shares are outstanding, with a floating share count of 72.80M. Insiders hold about 0.55% of the company’s shares, while institutions hold 95.96% stake in the company. Shares short for WST as of Feb 29, 2024 were 1.2M with a Short Ratio of 2.19, compared to 1.16M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.64% and a Short% of Float of 2.15%.
Dividends & Splits
WST’s forward annual dividend rate is 0.78, up from 0.77 a year ago. Against a Trailing Annual Dividend Yield of 0.20%, it implies a Forward Annual Dividend Yield of 0.20%. The stock’s 5-year Average Dividend Yield is 0.27. The current Payout Ratio is 9.90% for WST, which recently paid a dividend on May 01, 2024 with an ex-dividend date of Apr 23, 2024. Stock splits for the company last occurred on Sep 27, 2013 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 8 analysts. On average, analysts expect EPS of $1.3 for the current quarter, with a high estimate of $1.53 and a low estimate of $1.2, while EPS last year was $1.98. The consensus estimate for the next quarter is $1.98, with high estimates of $2.1 and low estimates of $1.82.
Analysts are recommending an EPS of between $7.89 and $7.5 for the fiscal current year, implying an average EPS of $7.61. EPS for the following year is $9.05, with 9 analysts recommending between $9.5 and $8.54.
Revenue Estimates
8 analysts predict $670.3M in revenue for the current quarter. It ranges from a high estimate of $676.6M to a low estimate of $657.09M. As of the current estimate, West Pharmaceutical Services, Inc.’s year-ago sales were $698.19M, an estimated decrease of -4.00% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $756.75M, an increase of 0.10% over than the figure of -$4.00% in the same quarter last year. There is a high estimate of $768.1M for the next quarter, whereas the lowest estimate is $730M.
A total of 9 analysts have provided revenue estimates for WST’s current fiscal year. The highest revenue estimate was $3.02B, while the lowest revenue estimate was $3B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.95B, up 2.10% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $3.28B in the next fiscal year. The high estimate is $3.34B and the low estimate is $3.24B. The average revenue growth estimate for next year is up 9.10% from the average revenue estimate for this year.
